Candel Therapeutics, Inc. (CADL)
$9.78-1.61%Close
SELLCRISIS · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $717M
- Beta
- -0.47
- P/E (TTM)
- -7.00
- Short % float
- 27.40%
- Days to cover
- 11.2
- SI change
- +5.3%
- 1W
- -4.40%
- 1M
- -7.30%
- vs SPY 1W
- -4.82%
- vs SPY 1M
- -9.36%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on CADL?
- LOPJLB’s latest quantitative signal on Candel Therapeutics, Inc. (CADL) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CADL in?
- Candel Therapeutics, Inc. (CADL) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Candel Therapeutics, Inc. (CADL) do?
- Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trial…